RECRUITING Not applicable ClinicalTrials.gov

Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis

Sponsor: Bone Biologics Corp • ClinicalTrials.gov ID: NCT03810573

Registry updated: 2026-10-15

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The objective of this clinical study is to evaluate the safety and effectiveness of NB1 Bone Graft in subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion. It is estimated that up to 30 participants will be enrolled in approximately 3 clinical sites. During baseline and follow-up assessments, patients will be asked to undergo x-rays and CT scans; adverse events and immunology will be collected, and; participants will be requested to complete participant questionnaires regarding quality of life, pain and function.

Interventions

NB1 (Device)
rhNELL-1/DBX

Eligibility criteria

Inclusion Criteria: * Documented diagnosis of degenerative disc disease * Up to Grade I spondylolisthesis * Eligible to undergo a single vertebral level spine fusion (L2 to S1) Exclusion Criteria: * Previous spinal instrumentation or previous interbody fusion procedure at the involved level * Grade II or greater spondylolisthesis * Systemic or local infection at the site of surgery

Conditions

Degenerative Disc Disease Spondylolisthesis

Locations

Monash Medical Center — Clayton, Victoria, Australia
St Vincent Melbourne — Fitzroy, Australia

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment